Allergy最新文献

{"title":"Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis.","authors":"Rinkesh K Gupta, Daniela Salgado Figueroa, Ferhat Ay, Benjamin Causton, Shahla Abdollahi, Michael Croft","doi":"10.1111/all.16412","DOIUrl":"https://doi.org/10.1111/all.16412","url":null,"abstract":"<p><strong>Background: </strong>Blocking IL-13 is highly efficacious in patients with Th2-biased atopic dermatitis (AD), and recent clinical data have highlighted that targeting the T cell costimulatory molecules OX40 and OX40L (TNFSF4) holds promise for future treatment of AD.</p><p><strong>Aim: </strong>We asked whether targeting another T cell costimulatory molecule, CD30L (TNFSF8), might also be a possible treatment option in AD.</p><p><strong>Methods: </strong>Single-cell RNA-seq data from human AD skin lesions was analyzed to identify pathogenic IL-13- or IL-22-producing T cells and assess expression of CD30 and its ligand in comparison to OX40 and its ligand. Additionally, a murine model of AD with repetitive exposure to house dust mite allergen was used to compare neutralizing antibodies against CD30L with those against IL-13 or OX40L.</p><p><strong>Results: </strong>Analysis of several scRNA-seq datasets from skin lesions of AD patients showed that transcripts for CD30 or CD30L were found expressed with OX40 or OX40L in the primary T cell populations that also expressed mRNA for IL13 and/or IL22. Suggesting that this could be therapeutically relevant, mice treated prophylactically with a blocking CD30L antibody were protected from developing maximal allergen-induced AD features, including epidermal and dermal thickening, immune cell infiltration, and expression of AD-related genes, similar to mice treated with a blocking IL-13 antibody. Moreover, therapeutic neutralization of CD30L in mice with experimental AD also reduced all of the pathological skin lesion features to a comparable extent as blocking OX40L.</p><p><strong>Conclusion: </strong>These data suggest that targeting the CD30-CD30L axis might hold promise as a future therapeutic intervention in human AD, similar to targeting the OX40-OX40L axis.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142714955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of Tight Junction Protein MAGI1 by Interferon-γ Contributes to Barrier Dysfunction in Chronic Rhinosinusitis With Nasal Polyps.","authors":"Jing Song, Chaoran Zhao, Enhao Wang, Jing Yuan, Chengshuo Wang, Ming Wang, Luo Zhang","doi":"10.1111/all.16405","DOIUrl":"https://doi.org/10.1111/all.16405","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of oral immunotherapy in hazelnut allergy: Pediatric experience in Toulouse.","authors":"N Casanovas, V Gruzelle, A Broue-Chabbert, R Pontcharraud, J Kamphuis, A Martin-Blondel, L Guilleminault, M Michelet","doi":"10.1111/all.16385","DOIUrl":"https://doi.org/10.1111/all.16385","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endogenous Glucagon-Like Peptide-1 Receptor and Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Inhibits Aeroallergen-Induced Innate Airway Inflammation","authors":"Shinji Toki,&nbsp;Masako Abney,&nbsp;Jian Zhang,&nbsp;Mark Rusznak,&nbsp;Christian M. Warren,&nbsp;Dawn C. Newcomb,&nbsp;Katherine N. Cahill,&nbsp;Daniel J. Drucker,&nbsp;Kevin D. Niswender,&nbsp;Ray Stokes Peebles Jr.","doi":"10.1111/all.16402","DOIUrl":"10.1111/all.16402","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Anti-inflammatory effects of incretin signaling through the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) in mice have been reported. Therefore, we hypothesized that signaling through the endogenous GLP-1R and the GIPR individually decreases allergic airway inflammation and that the combination of GLP-1R and GIPR signaling together additively inhibits allergen-induced lung and airway inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>WT (C57BL/6J), GLP-1R knockout (KO), GIPR KO, and GLP-1R/GIPR double KO (DKO) mice were challenged intranasally with <i>Alternaria alternata</i> extract (Alt-Ext) or vehicle to evaluate the impact of signaling through these receptors on the innate allergen-induced inflammatory response that is primarily driven by group 2 innate lymphoid cells (ILC2).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Alt-Ext-induced IL-33 release in the bronchoalveolar lavage fluid (BALF) was not different between the mouse strains, but thymic stromal lymphopoietin (TSLP) was significantly increased in GLP-1R/GIPR DKO mice challenged with Alt-Ext compared to the other strains. Furthermore, Alt-Ext-induced protein expression of IL-5, IL-13, CCL11, and CCL24 in the lung homogenates, the number of eosinophils, lymphocytes, and neutrophils in the BALF, and the number of lung GATA3+ ILC2 were significantly increased in GLP-1R/GIPR DKO mice compared to the other 3 strains. Furthermore, ICAM-1 expression on lung epithelial cells was increased in GLP-1R/GIPR DKO mice challenged with Alt-Ext compared to the other 3 strains.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Deficiency of both GLP-1R and GIPR signaling together increased TSLP release, ILC2 activation, and early type 2 innate immune responses to aeroallergen exposure. Combined GLP-1R and GIPR signaling should be explored for the treatment of asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 12","pages":"3373-3384"},"PeriodicalIF":12.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence Survey on Oral Allergy Syndrome in Patients With Seasonal Allergic Rhinitis in Yamanashi, Japan.","authors":"Ayumi Shimamura, Hiroki Ishii, Tomokazu Matsuoka, Daisuke Watanabe, Takaaki Yonaga, Keisuke Masuyama, Daiju Sakurai","doi":"10.1111/all.16398","DOIUrl":"https://doi.org/10.1111/all.16398","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142646428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.","authors":"Bernardo Sousa-Pinto, Rafael José Vieira, Antonio Bognanni, Sara Gil-Mata, Renato Ferreira-da-Silva, André Ferreira, António Cardoso-Fernandes, Henrique Ferreira-Cardoso, Manuel Marques-Cruz, Vítor Henrique Duarte, João Castro-Teles, Miguel Campos-Lopes, Ana Teixeira-Ferreira, Nuno Lourenço-Silva, Ivan Chérrez-Ojeda, Anna Bedbrook, Ludger Klimek, Juan Jose Yepes Nuñez, Torsten Zuberbier, João A Fonseca, Holger J Schünemann, Jean Bousquet","doi":"10.1111/all.16384","DOIUrl":"https://doi.org/10.1111/all.16384","url":null,"abstract":"<p><strong>Background: </strong>Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network-meta-analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR.</p><p><strong>Methods: </strong>We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events. Certainty of evidence was assessed using GRADE-NMA.</p><p><strong>Results: </strong>We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ranked interventions for efficacy outcomes, being regularly associated with clinically meaningful larger improvements when compared to other active treatments. Considering drug classes, INAH+INCS were the highest-ranked interventions for all outcomes in which they were assessed, followed in most cases by INCS. In 105 out of 184 comparisons in seasonal AR, and 28 out of 97 comparisons in perennial AR, certainty of evidence was considered \"high\" or \"moderate\".</p><p><strong>Conclusion: </strong>Intranasal medications for AR display clinically relevant differences in their efficacy, but all show a good safety profile. To our knowledge, this is the first network meta-analysis comparing INAH, INCS, and INAH+INCS in AR, providing relevant evidence for guideline developers and practising physicians on the most efficacious treatments.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracing the evolutionary pathway of IgG4: Implications for immune tolerance and regulation.","authors":"Huseyn Babayev, Ali Sahin, Sena Ardicli, Mubeccel Akdis, Cezmi A Akdis","doi":"10.1111/all.16383","DOIUrl":"https://doi.org/10.1111/all.16383","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-33 Sensitizes Mast Cells to PIEZO1 Stimulation Leading to Degranulation","authors":"Yoshiaki Kobayashi,&nbsp;Kent Sakai,&nbsp;Nguyen Quoc Vuong Tran,&nbsp;Kayoko Ishimaru,&nbsp;Takuya Sato,&nbsp;Yuki Nakamura,&nbsp;Daiki Nakagomi,&nbsp;Satoshi Tanaka,&nbsp;Schuichi Koizumi,&nbsp;Atsuhito Nakao","doi":"10.1111/all.16397","DOIUrl":"10.1111/all.16397","url":null,"abstract":"&lt;p&gt;PIEZO1 is a mechanosensitive calcium-permeable ion channel that converts mechanical stimuli into biological signals [&lt;span&gt;1&lt;/span&gt;]. PIEZO1 plays important roles in innate immune cells including monocytes and natural killer cells [&lt;span&gt;2, 3&lt;/span&gt;]. However, the role of &lt;i&gt;Piezo1&lt;/i&gt; in mast cells remains unexplored. Mast cells release histamine in response to mechanical stimuli such as pressure, which triggers itching in a subset of patients with chronic inducible urticaria [&lt;span&gt;4&lt;/span&gt;]. We therefore investigated the connection between PIEZO1 and mast cells.&lt;/p&gt;&lt;p&gt;First, we examined &lt;i&gt;Piezo1&lt;/i&gt; mRNA expression in mouse bone marrow–derived mast cells (BMMCs) in the presence or absence of various stimuli. We found that IL-33, SCF, and IgE significantly upregulated &lt;i&gt;Piezo1&lt;/i&gt; mRNA expression compared with that in the control (Figure 1A). Notably, IL-33 caused an approximately 20-fold increase in Piezo1 mRNA levels. Consistent with these findings, analysis of IL-33–induced gene expression patterns in BMMCs from a Gene Expression Omnibus dataset (GSE96695) identified &lt;i&gt;Piezo1&lt;/i&gt; as one of the top upregulated genes (Figure S1). &lt;i&gt;Piezo1&lt;/i&gt; mRNA levels also increased in mouse connective tissue–type mast cells (CTMCs) stimulated with IL-33 (Figure S2A), and IL-33 stimulation upregulated PIEZO1 protein expression in BMMCs (Figure 1B). These findings suggest that IL-33 induces PIEZO1 expression in mouse mast cells.&lt;/p&gt;&lt;p&gt;We then assessed the functional role of IL-33–induced PIEZO1 in mast cells. We measured intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; levels in response to stimulation with Yoda1, a specific PIEZO1 activator [&lt;span&gt;5&lt;/span&gt;], in IL-33–pretreated or IL-33–untreated BMMCs. Yoda1 increased intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; levels in IL-33–pretreated, but not in IL-33–untreated BMMCs (Figure 1C). Consistently, Yoda1 stimulation induced degranulation responses in IL-33–pretreated, but not in IL-33–untreated BMMCs, as determined by measuring β-hexosaminidase release and CD63 expression, which were reduced by siRNA-mediated &lt;i&gt;Piezo1&lt;/i&gt; knockdown (Figure 1D–F and Figure S3). In addition, Yoda1 stimulation induced the release of histamine, prostaglandin D2 (PGD2), leukotrienes (LTC4/D4/E4), and cytokines (IL-4 and IL-13) in IL-33–pretreated, but not in IL-33–untreated BMMCs (Figure 1G and Figure S4). The release of both β-hexosaminidase and histamine was suppressed by EGTA, a calcium chelator (Figure 1D,G), suggesting that Ca&lt;sup&gt;2+&lt;/sup&gt; influx via PIEZO1 plays a role in these responses. Similar results were obtained in CTMCs (Figure S2B,C). IL-33 also upregulated PIEZO1 in human mast cells (huMCs) derived from CD34&lt;sup&gt;+&lt;/sup&gt; stem cells isolated from human peripheral blood (Figure 1H and Figure S5A). Furthermore, IL-33–pretreated, but not IL-33–untreated huMCs increased CD63 expression upon Yoda1 stimulation (Figure 1I and Figure S5B). These findings suggest that IL-33 induction of PIEZO1 in mast cells leads to degranulation and the release of ","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 12","pages":"3517-3520"},"PeriodicalIF":12.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16397","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142637952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Milk Microbiome Is Associated With Allergic Diseases in Early Childhood","authors":"Jie Ma,&nbsp;Debra J. Palmer,&nbsp;Donna Geddes,&nbsp;Ching Tat Lai,&nbsp;Susan L. Prescott,&nbsp;Nina D'Vaz,&nbsp;Philip Vlaskovsky,&nbsp;Lisa F. Stinson","doi":"10.1111/all.16399","DOIUrl":"10.1111/all.16399","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 12","pages":"3509-3511"},"PeriodicalIF":12.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable.","authors":"M Jutel, C Vogelberg, K Duwensee, D Troyke, L Klimek","doi":"10.1111/all.16370","DOIUrl":"https://doi.org/10.1111/all.16370","url":null,"abstract":"<p><strong>Background: </strong>Allergen immunotherapy (AIT) aims at modulating the immune response by administration of allergen preparations at regular intervals over several years (1). For subcutaneous AIT (SCIT), the treatment is initiated with a dose escalation phase followed by a maintenance dose administration. Over the last decade, there has been a trend towards shortening dose escalation regimens to increase patient adherence. This open-label, phase II trial aimed to investigate the safety and tolerability of a house dust mites (HDMs) SCIT product when used in a newly designed one-strength dose escalation scheme.</p><p><strong>Method: </strong>Patients, aged 12-65, suffering from HDM-allergic rhinitis/rhinoconjunctivitis ± asthma were included. Patients were randomized to the one-strength (6 injections from the highest strength 3) or the Standard dose escalation regimen (14 injections from strengths 1 to 3) using the HDMs-SCIT product. All adverse events were reported. Tolerability was assessed on the Likert scale.</p><p><strong>Results: </strong>One hundred and forty-three patients were randomized, 79 adults and 64 adolescents. In total, the one-strength regimen caused more adverse drug reactions (ADRs) than the Standard regimen (p = .0457). With both regimens most ADRs were local reactions which occurred more often in the one-strength group (p = .0393). But there was no significant difference in the number of patients affected by systemic or serious ADRs between both regimens. No relevant differences occurred between the two age groups and no other risks were observed for adolescents compared to adults.</p><p><strong>Conclusion: </strong>The safety and tolerability of both regimens can be considered comparable, as most ADRs were local reactions, primarily rated as mild in intensity. Nevertheless, the one-strength regimen caused more ADRs. Reducing the number of injections from 14 to 6 while using only one strength offers the potential to improve patient adherence which further might increase clinical efficacy. Future trials could confirm this hypothesis.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}